Evidence map›Paper›PMID 31216563›Full record

ArticleNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2020

(2R,6R)-hydroxynorketamine rapidly potentiates hippocampal glutamatergic transmission through a synapse-specific presynaptic mechanism.

Lace M Riggs, Yasco Aracava, Panos Zanos, Jonathan Fischell, Edson X Albuquerque, Edna F R Pereira, Scott M Thompson, Todd D Gould

Open access · bronzeAbstract read
In one paragraph

Article in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
6.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 66 citations in OpenAlex.

  1. Trial
  2. Sex-dependent metabolism of ketamine and (Journal of psychopharmacology (Oxford, England) · 2022
    Trial
  3. Ketamine metabolites, clinical response, and gamma power in a randomized, placebo-controlled, crossover trial for treatment-resistant major depression.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2020
    Trial
  4. Review
  5. Article
  6. Article
  7. A Time-Sensitive Plasticity Distinguishes the Rapid and Sustained Synaptic Actions of Ketamine from Its (2The Journal of neuroscience : the official journal of the Society for Neuroscience · 2026
    Article
  8. Prefrontal contribution to passive coping behaviour in chronic stress and treatment by fast-acting antidepressant.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026
    Article
  9. The hippocampus as a central hub in ketamine's antidepressant action: from molecules to circuit rewiring.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026
    Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Rapid hippocampal synaptic potentiation induced by ketamine metabolite (2R,6R)-hydroxynorketamine persistently primes synaptic plasticity.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2025
    Article
  15. Review
  16. Article
  17. Review
  18. NMDA Receptor Activation-Dependent Antidepressant-Relevant Behavioral and Synaptic Actions of Ketamine.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2023
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Lace M RiggsProgram in Neuroscience, University of Maryland School of Medicine, Baltimore, MD, 21201, USA.ORCID http://orcid.org/0000-0003-4368-4089
Yasco AracavaDepartment of Epidemiology and Public Health, Division of Translational Toxicology, University of Maryland School of Medicine, Baltimore, MD, 21201, USA.
Panos ZanosDepartment of Psychiatry, University of Maryland School of Medicine, Baltimore, MD, 21201, USA.
Jonathan FischellDepartment of Physiology, University of Maryland School of Medicine, Baltimore, MD, 21201, USA.
Edson X AlbuquerqueDepartment of Epidemiology and Public Health, Division of Translational Toxicology, University of Maryland School of Medicine, Baltimore, MD, 21201, USA.
Edna F R PereiraDepartment of Epidemiology and Public Health, Division of Translational Toxicology, University of Maryland School of Medicine, Baltimore, MD, 21201, USA.
Scott M ThompsonDepartment of Psychiatry, University of Maryland School of Medicine, Baltimore, MD, 21201, USA.
Todd D GouldDepartment of Psychiatry, University of Maryland School of Medicine, Baltimore, MD, 21201, USA. gouldlab@me.com.
University of Maryland, Baltimore · US

Funding

EXPAND PARTICIPATION BY MINORITIES IN BIOMEDICAL SCIENCER25GM055036 · NIGMS · UNIVERSITY OF MARYLAND BALTIMORE COUNTY · PI SUMMERS, MICHAEL FINLEY · 1996 to 2021
$16.9M
Therapeutic Efficacy of Ketamine Metabolites for Depression TreatmentR01MH107615 · NIMH · UNIVERSITY OF MARYLAND BALTIMORE · PI GOULD, TODD D · 2016 to 2025
$7.2M
TRAINING PROGRAM IN INTEGRATIVE MEMBRANE BIOLOGYT32GM008181 · NIGMS · UNIVERSITY OF MARYLAND BALTIMORE · PI RIZZO, MEGAN A, TRUDEAU, MATTHEW C · 1987 to 2022
$4.9M
Training Program in NeuroscienceT32NS063391 · NINDS · UNIVERSITY OF MARYLAND BALTIMORE · PI Jessica Aurora Mong · 2008 to 2026
$4.0M
Stress, Depression, Serotonin, and Plasticity of Excitatory TransmissionR01MH086828 · NIMH · UNIVERSITY OF MARYLAND BALTIMORE · PI THOMPSON, SCOTT M. · 2010 to 2019
$3.8M
Synaptic mechanisms underlying the rapid antidepressant properties of the (2R,6R)-hydroxynorketamine metaboliteF31MH123066 · NIMH · UNIVERSITY OF MARYLAND BALTIMORE · PI RIGGS, LACE MARIE · 2020 to 2021
$55k
BLRD VA I01 BX004062NIGMS NIH HHS R25 GM055036NIGMS NIH HHS T32 GM008181NIMH NIH HHS F31 MH123066NIMH NIH HHS R01 MH086828NIMH NIH HHS R01 MH107615NINDS NIH HHS T32 NS063391
6 · The paper itself

Abstract

Preclinical studies indicate that (2R,6R)-hydroxynorketamine (HNK) retains the rapid and sustained antidepressant-like actions of ketamine, but is spared its dissociative-like properties and abuse potential. While (2R,6R)-HNK is thought to exert its antidepressant-like effects by potentiating α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR)-mediated synaptic transmission, it is unknown how it exerts this effect. The acute synaptic effects of (2R,6R)-HNK were examined by recording field excitatory postsynaptic potentials (fEPSPs) and miniature excitatory postsynaptic currents (mEPSCs) in rat hippocampal slices. (2R,6R)-HNK bath application caused a rapid and persistent potentiation of AMPAR-mediated Schaffer collateral (SC)-CA1 fEPSPs in slices derived from male and female rats. The (2R,6R)-HNK-induced potentiation occurred independent of N-methyl-D-aspartate receptor (NMDAR) activity, was accompanied by a concentration-dependent decrease in paired pulse ratios, and was occluded by raising glutamate release probability. In additon, in the presence of tetrodotoxin, (2R,6R)-HNK increased the frequency, but not amplitude, of mEPSC events, confirming a presynaptic site of action that is independent of glutamatergic network disinhibition. A dual extracellular recording configuration revealed that the presynaptic effects of (2R,6R)-HNK were synapse-selective, occurring in CA1-projecting SC terminals, but not in CA1-projecting temporoammonic terminals. Overall, we found that (2R,6R)-HNK enhances excitatory synaptic transmission in the hippocampus through a concentration-dependent, NMDAR-independent, and synapse-selective increase in glutamate release probability with no direct actions on AMPAR function. These findings provide novel insight regarding (2R,6R)-HNK's acute mechanism of action, and may inform novel antidepressant drug mechanisms that could yield superior efficacy, safety, and tolerability.

Indexed as

AnimalsExcitatory Postsynaptic PotentialsFemaleGlutamic AcidHippocampusKetamineMaleOrgan Culture TechniquesPresynaptic TerminalsRatsRats, Sprague-DawleySynapsesSynaptic Transmission6-hydroxynorketamineGlutamic AcidKetamine

Identifiers

PMID31216563
PMCPMC6901515
OpenAlexW2953365016

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.